Hospital

Relevant training and credentials lead to technicians taking a more active role in pharmacies.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Blue Earth Therapeutics will begin an open-label, multicenter trial to evaluate a next-generation radiopharmaceutical for metastatic castration-resistant prostate cancer.

It is imperative for health care professionals, especially pharmacists, to be well-informed regarding the physiological impact of Ramadan on diabetes.

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Ravulizumab-cwvz (Ultomiris) produced statistically significant improvements in measures of functional activity, muscle strength, and quality of life in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Biosimilars could save consumers more than $100 billion in the coming years.

Britny Brown, PharmD, BCOP, vice chair of the Hematology/Oncology Pharmacy Association (HOPA) DEI Task Force and clinical assistant professor at the University of Rhode Island College of Pharmacy, discusses the role of the task force within HOPA and its impact on the field more broadly.

Individuals with immunity obtained through having the disease still experienced expanded T-cell memory and immune activation after being immunized, study results show.

Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Study results show at a molecular level how fidaxomicin selectively targets these bacteria, while sparing others in the gut microbiome.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

Strong support from pharmacy professionals and a shift in systems and workflows help pave the way for success.

Cutaneous squamous cell carcinoma should be diagnosed early and treated promptly to avoid complications.

A multidisciplinary team of nurse practitioners and pharmacists can work together to address patients at an increased risk for hospital readmission.

In studies of rats, results show that supplementation preserves skeletal muscle after patients take the chemotherapy medication doxorubicin.

A variety of strategies can help increase patient adherence to oral chemotherapy.

Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.

In an interview with Pharmacy Times®, Ryan Haumschild, PharmD, MS, MBA director of pharmacy at Emory Healthcare and Winship Cancer Institute, discusses the pharmacists role in care teams for targeted therapies at the Academy of Managed Care Pharmacy Annual Meeting.

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo.

Technology clears the way to offer clinical-focused tasks, ultimately improving job satisfaction and minimizing burnout.

Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.

Genome sequencing shows the clonality of outbreak isolates within each of 6 classes, which confirmed that recent transmissions accounted for high carriage.

Betrixaban (Bevyxxa) is a factor Xa inhibitor indicated for the prophylaxis of venous thromboembolism in adult patients.

On average, patients visit their community pharmacist 12 times more often than they do their primary care provider